Yaws medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
The mainstay of therapy for yaws is antimicrobial therapy. Pharmacologic therapy for yaws includes either [[Phenoxymethylpenicillin]], [[Tetracyclines]], [[Doxycycline]], [[Erythromycin]], or [[Azithromycin]]. Close contacts of patients must be examined and treated for yaws if the disease is present. | |||
==Medical therapy== | ==Medical therapy== | ||
| Line 10: | Line 11: | ||
*Yaws<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530 }} </ref> | *Yaws<ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530 }} </ref> | ||
:* Preferred regimen (1): [[Phenoxymethylpenicillin]] 12.5 mg/kg q6h 7-10days (maximum dose, 300 mg q6h) | :* Preferred regimen (1): [[Phenoxymethylpenicillin]] 12.5 mg/kg q6h 7-10days (maximum dose, 300 mg q6h) | ||
:* Preferred regimen (2): [[Tetracyclines]] 500 mg q6h 15 days or [[ | :* Preferred regimen (2): [[Tetracyclines]] 500 mg q6h 15 days or [[Doxycycline]] 100 mg q12h (alternative agents for the treatment of yaws in nonpregnant adults) | ||
:* Preferred regimen (3): [[Erythromycin]] 8–10 mg/kg 15 days q6h | :* Preferred regimen (3): [[Erythromycin]] 8–10 mg/kg 15 days q6h | ||
:* Preferred regimen (4): [[Azithromycin]] 30 mg/kg single-dose (maximum dose 2 g) | :* Preferred regimen (4): [[Azithromycin]] 30 mg/kg single-dose (maximum dose 2 g) | ||
| Line 18: | Line 19: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
[[Category: Infectious Disease Project]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 19:29, 18 September 2017
|
Yaws Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Yaws medical therapy On the Web |
|
American Roentgen Ray Society Images of Yaws medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The mainstay of therapy for yaws is antimicrobial therapy. Pharmacologic therapy for yaws includes either Phenoxymethylpenicillin, Tetracyclines, Doxycycline, Erythromycin, or Azithromycin. Close contacts of patients must be examined and treated for yaws if the disease is present.
Medical therapy
- Yaws[1]
- Preferred regimen (1): Phenoxymethylpenicillin 12.5 mg/kg q6h 7-10days (maximum dose, 300 mg q6h)
- Preferred regimen (2): Tetracyclines 500 mg q6h 15 days or Doxycycline 100 mg q12h (alternative agents for the treatment of yaws in nonpregnant adults)
- Preferred regimen (3): Erythromycin 8–10 mg/kg 15 days q6h
- Preferred regimen (4): Azithromycin 30 mg/kg single-dose (maximum dose 2 g)
References
- ↑ Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL; et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.